References
- . Chou R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn. 2009;119(7–8):469–477
- . Sinatra R. Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain. J Am Board Fam Med. 2006;19(2):165–177
- . Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11( 2 suppl):S133–S153
- . Benyamin R, Trescot AM, Datta S, . Opioid complications and side effects. Pain Physician. 2008;11( 2 suppl):S105–S120
- . Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29
- . Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucml11350.htm. Accessed November 28, 2011
- . Nucynta [package insert]. Titusville, NJ: Ortho-McNeil Janssen Pharmaceuticals, Inc.; 2011
- . Nucynta ER [package insert]. Titusville, NJ: Ortho-McNeil Janssen Pharmaceuticals, Inc.; 2011
- . Hartrick CT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother. 2009;10(16):2687–2696
- . Frampton JE. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs. 2010;70(13):1719–1743
- . Schwartz S, Etropolski M, Shapiro DY, . Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–162
- . Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009;25(5):1095–1104
- . Oxecta [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2011
- . Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24(10):805–810
- . Pfizer and Acura announce FDA approval of Oxecta$tM (oxycodone HCL, USP) CIL http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&newsId=20110620005857&newsLang=en. Accessed November 18, 2011
- . Raffa RB, Pergolizzi JV Jr. Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example. J Clin Pharm Ther. 2011;36(3):283–298
- . Acura Pharmaceuticals, Inc. Abuse deterrent products, http://acurapharm.com/research-development/aversion-technology/intravenous-injection/. Accessed November 17, 2011
- . Oxycontin [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010
- . Food and Drug Administration. FDA epidemiology advisory committee meeting. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM233243.pdf. Accessed December 5, 2011
- . http://www.ClinicalTrials.gov. To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin$rG (OXY) Tablets. NCT01101178. Accessed November 21, 2011
- . Pfizer pipeline—our medicines in development. http://www.pfizer.com/research/product_pipeline/product_pipeline.jsp. Accessed November 21, 2011
- . Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the management of pain. Drugs. 2010;70(1):57–72
- . Food and Drug Administration. Orange book: approved drag products with therapeutic equivalence evaluations, http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed December 5, 2011
- . Abstral [package insert]. Bedminster, NJ: ProStrakan, Inc.; 2011
- . Actiq [package insert]. Frazer, PA: Cephalon, Inc.; 2011
- . Fentora [package insert]. Frazer, PA: Cephalon, Inc.; 2011
- . Lazanda [package insert]. Bedminster, NJ: Archimedes Development Ltd.; 2011
- . Onsolis [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2009
- . Landy SH. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series. Headache. 2004;44(8):762–766
- . Shear ML, Adler JN, Shewakramani S, . Transbuccal fentanyl for rapid relief of orthopedic pain in the ED. Am J Emerg Med. 2010;28(8):847–852
- . Lichtor JL, Sevarino FB, Joshi GP, Busch MA, Nordbrock E, Ginsberg B. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg. 1999;89(3):732–738
- . Mandel L, Carunchio MJ. Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. J Am Dent Assoc. 2011;142(4):406–409
- . Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011;112(3):693–702
- . The FOCUS$tM program for Onsolis$tM. http://www.onsolisfocus.com/prescriber/index.html. Accessed December 5, 2011
- . Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. 2011;11(8):1197–1216
- . US Food and Drug Administration. Information for healthcare professionals: hydromorphone hydrochloride extended-release capsules (marketed as Palladone). http://www.fda.gov/Drags/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucml29288.htm. Accessed November 28, 2011
- . Exalgo [package insert]. Vacaville, CA: ALZA Corporation; 2010
- . Drover DR, Angst MS, Valle M, . Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002;97(4):827–836
- . Wallace M, Moulin DE, Rauck RL, . Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag. 2009;5(2):97–105
- . Carter NJ, Keating GM. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain. CNS Drugs. 2010;24(4):337–361
- . US Food and Drug Administration. Background on opioid REMS, http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucml87975.htm. Accessed November 28, 2011
- . Butrans [package insert]. Stamford, CT: Purdue Pharma L.P.; 2011
- . Gordon A, Rashiq S, Moulin DE, . Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010;15(3):169–178
- . Przeklasa-Muszynska A, Dobrogowski J. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland. Curr Med Res Opin. 2011;27(6):1109–1117
- . Embeda [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2009
- . Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med. 2010;122(4):112–128
- . Pfizer Inc. Statement on voluntary recall of embeda(r) extended release capsules CIL http://www.pfizer.com/files/news/embeda_recall_031611.pdf. Released March 15, 2011. Accessed January 5, 2012